Obstetric antiphospholipid antibody syndrome (APS), is well defined by classification criteria. It is well known that women with APS should receive prophylactic anticoagulation therapy with subcutaneous low weight heparin all throughout pregnancy and in the first 6 weeks postpartum. However, the optimal treatment for pregnant women having positive anti-phospholipid antibodies, but not fullfilling classification criteria for APS is still unclear. In this retrospective study we report pregnancy outcomes of 10 patients affected by recurrent miscarriages and positive anti-cardiolipin or ap2GPl antibodies with titers ranging from 10 to 20 GPLIMPL demonstrated at least twice before pregnancy.
Antiphospholipid antibody syndrome (APS), which may occur primarily or secondary to other systemic diseases, is defined by the presence of vascular thrombosis and/or pregnancy morbidity with persistently positive anti-phospholipid antibodies (aPLs) at titers> 40 GPL or MPL or the 99 th percentile (1) . Despite positive aPLs being detectable in about 2% of the general population, APS is a rare disease. Anti-cardiolipin antibodies (aCL), anti-Bzglicoproteinl antibodies (anti-~2GPI) and lupus anticoagulant (LA) are all aPLs (l).
Obstetrical APS is well defined by classification criteria (1, 2) . Moreover women with diagnosis of APS, during pregnancy, are at increased risk for arterial and venous thrombosis (3) . It is well known that women with APS should receive prophylactic anticoagulation therapy with subcutaneous low weight heparin throughout all pregnancy and in the first 6 weeks postpartum (3, 4) . However, the optimal treatment for pregnant women having positive aPLs, but not fullfilling classification criteria for APS is still unclear. In this study, from 250 clinical records of patients attending our outpatients clinic, we retrospectively evaluated clinical records ofl Owomen with apparently unexplained recurrent miscarriages and positive aCL or a~2GP 1 antibodies at very low titers (between 10 and 20 GPLlMPL), demonstrated at least twice before pregnancy, who again became pregnant. Exclusion criteria were: i) positive aCL or a~2GPI antibodies at diagnostic titers or positive LA; ii) systemic autoimmune diseases including APS; iii) known genetic, hormonal, infective or anatomic causes of recurrent miscarriages. In each patient aCL, a~2GP1, LA, antinuclear antibodies (ANA) and extractable nuclear antigen (ENA) profile were assessed before conception and every 2 months during pregnancy. Moreover, prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen (FBG), antithrombin III (ATIII), Factor V Leiden (FVL), activated protein C (APC)-resistance, prothrombin G202I0A gene mutation (FII202I0), C677T methylenetetrahydropholate reductase (MTHFR) gene mutations and homocysteine (Hy) were evaluated.
Our results showed that the patients' mean age was 38.5+3.62 years. All 10 patients reported at least 3 previous miscarriages. Miscarriagess mainly occurred within the first trimester, with the exception of 3 patients who miscarried during the second trimester, and of one who gave birth to a stillborn in the 8 th month of pregnancy. Autopsy demonstrated, in all these 4 cases, normal fetal morphology and placental abnormalities including thrombosis. All 10 patients had repeatedly positive aPL antibodies with titres ranging from 10 to 20 GPLlMPL demonstrated at least twice before pregnancy (Table  I ). In particular, 6/10 had positive IgM aCL, of whom two had also positive IgG a~2GPI, lIlO was only IgG a~2GPI positive and 3/10 had positive aCL IgG. Only one woman once showed positive LA. Moreover 6/10 displayed also positive ANA at titres ranging from I :80 to I :320 and 2/10 patients showed positive anti-SSA, with no clinical signs of related disease. In these last two patients serial cardiac fetal beat monitoring and echocardiogram during all the pregnancy had been carried out showing no abnormalities (5) . An increase of aPL titers during pregnancy was documented in all the patients. A diagnosis of APS was made for 5/ I0 women since 4 patients became LA positive and I demonstrated an increase of aCL IgG titers up to 35 GPL, thus fulfilling consensus classification criteria (I). One out of the 10 patients developed positive ANA during pregnancy, showing also positive LA, malar rash and leucopenia, thus fulfilling classification criteria for systemic lupus erythematosus (SLE) (6), therefore she was excluded from the study. Among the remaining patients, 3 developed positive a~2GPI
IgG antibodies with titers ranging from 13 to 16 GPL (Table I) . Moreover, in 9/ 10 patients the co-existence of one or two congenital thrombophilic risk factors was observed: 7/9 women showed C677T MTHFR mutation either heterozygous (617) or homozygous (117), 4/9 patients had slight hyperhomocysteinemia (ranging between 12.5 and 15 mmoli/L); 6/9 carried FVL gene mutation with ACP-resistance and I was found to be positive for heterozygous FII202I 0 gene mutation. Only in one APS woman no congenital thrombophilic mutations were found. All 10 patients had undergone a daily oral acetylsalicylic acid (ASA 100 mg) administration before pregnancy. Low molecular weight subcutaneous heparin (enoxaparin 4000 IV once a day) was added after positive laboratory testing and was continued up to the 6 th week postpartum. Eight of our patients delivered regularly, the one with SLE did not attend further controls and one, who discontinued the therapy, experienced her 4 th miscarriage. After the first child, none of the patients tried to become pregnant again except for one who was included in the APS group. This woman, who had experienced 3 miscarriages before diagnosis was made, had 3 succeeding full-term pregnancies after administration of low weight heparin prophylaxis.
Our report demonstrates that repeated detection of positive aPLs, although at very low titres, may identify women with increased risk of obstetric complications related to APS or to other systemic autoimmune disease. Moreover, our results strongly suggest that pregnancy may represent a risk condition for the development and worsening of autoimmunity, since hormonal and antigenic stimuli drive the immune system toward a new immunological pattern (7) . Thus, it is likely that at least a part of women with history of apparently unexplained recurrent miscarriages and low titers of aPLs may have an undiagnosed APS, needing a multidisciplinary clinical approach. This is not surpnsmg since it is well known that aPL titers may float during time (1) . We, therefore, would underline, accordingly to the consensus statement on classification criteria (1) , that recurrent miscarriages, which represent a clinical criterion of obstetric APS, should be considered specific to identify patients with the syndrome, since the definition of levels of aPLs that best correspond to the risk of clinical manifestation is difficult to establish (1) . Moreover, we could speculate that in patients with poor organ involvement, systemic autoimmune diseases may remain undiagnosed. In agreement with such observation, we noticed that our women, who apparently did not display clinical signs of systemic autoimmunity, showed more than one positive auto-antibody. Taken together, these observations suggest that any positive auto-antibody in patients with a history of apparently unexplained recurrent miscarriages should give raise to the suspicion of a systemic autoimmune disease, which can underlie pregnancy disorders and maternal disease. Finally, in 9/ 10 of our women the presence of one or two co-existing congenital thrombophilic factors was found. Thrombophilic mutations have generally been associated with an increased risk of spontaneous abortions (8) (9) (10) (11) (12) . However, whether each thrombophilic factor is related to recurrent miscarriages or not is still under debate (11, 12), so that in pregnancy anticoagulant prophylaxis is recommended only in women with a previous thrombosis or history of miscarriages (4, 12) . To our knowledge, among all pro-thrombothic factors APCresistance, which was observed in 6/ I0 ofour patients, was that mainly related to pregnancy morbidity (II). In accordance with DeSancho (13), therefore, we hypothesized that the presence 2 or more prothrombotic factors, both congenital and acquired, by an additive mechanism, can precipitate a placental insufficiency. Antiphospholipid antibodies, indeed, may induce vessel damage, directly by triggering thrombosis, but also indirectly by binding to antigen targets on endothelial cells (14, 15) . Therefore, we could speculate that aPLs, at any titer, may induce such endothelial damage, which represents the predisposing substrate for thrombofilic factors to act. Since recurrent miscarriages represent a dramatic event with a potential negative impact on the physical and mental health of a woman, we strongly recommend to evaluate aPLs and thrombofilic mutations in all patients with a history of recurrent miscarriages who want to become pregnant, with the aim of identifying those who need anticoagulant prophylaxis.
The study was carried out according to the principles of the Declaration of Helsinki. Written informed consent was obtained from each patient
